RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
February 03, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Feb. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit
September 09, 2019 17:13 ET
|
RespireRX Pharmaceuticals Inc.
September 10 – 12, 2019 Workshops, September 10, 2019 Aloft Boston Seaport District 401-403 D. St., Boston, MA 02210 Executive Chairman/CSO/Interim CEO...
RESPIRERX PHARMACEUTICALS INC. SEND NOTICE LETTER TO THE BOARD OF DIRECTORS OF THERAPIX BIOSCIENCES LTD.
July 30, 2019 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zealand and Southeast Asia
February 19, 2019 08:50 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
RespireRx Pharmaceuticals Inc. Appoints James Sapirstein as Executive Vice Chairman of the Board of Directors
January 03, 2019 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Jan. 03, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a clinical stage pharmaceutical company, focused on the development of...
RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit
December 10, 2018 08:35 ET
|
RespireRX Pharmaceuticals Inc.
December 11 – 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston, MA SVP R&D leading workshop on Financial Planning and Commercial DevelopmentSVP R&D to present...
RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc.
September 10, 2018 15:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on...
RespireRx Pharmaceuticals Inc. Announces Publication of Ampakine Data:
July 25, 2018 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Effects of Chronic Systemic Low-impact Ampakine Treatment on Neurotrophin Expression in Rat Brain Glen Rock, N.J., July 25, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI)...
RespireRx Pharmaceuticals Inc. Announces Resignation of Dr. James S. Manuso
June 19, 2018 16:14 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, June 19, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. announces the decision of Dr. James S. Manuso to resign as president, CEO, Vice Chairman and member of the Board of...
Advancing Dronabinol Obstructive Sleep Apnea Program with Letter of Intent for Co-Development and Supply Agreement with Noramco, Inc.
June 19, 2018 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., June 19, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on June 13, 2018, it entered into a letter...